Obesity is a chronic condition and a worldwide problem that poses health risks, reduces quality of life (QoL), contributes to psychosocial issues and increases public healthcare costs [1]. While, GLP1 agonists show promising short-term results for weight loss, their long-term efficacy remains unknown. In contrast, metabolic surgery has demonstrated sustained weight loss after long-term follow-up [2–4]. Additionally, metabolic surgery effectively addresses obesity-related comorbidities and improves QoL [4,5].
